Skip to main content
Top
Published in: Malaria Journal 1/2007

Open Access 01-12-2007 | Research

Antibodies elicited in adults by a primary Plasmodium falciparum blood-stage infection recognize different epitopes compared with immune individuals

Authors: Damon P Eisen, Lina Wang, Helene Jouin, E Elsa H Murhandarwati, Casilda G Black, Odile Mercereau-Puijalon, Ross L Coppel

Published in: Malaria Journal | Issue 1/2007

Login to get access

Abstract

Background

Asexual stage antibody responses following initial Plasmodium falciparum infections in previously healthy adults may inform vaccine development, yet these have not been as intensively studied as they have in populations from malaria-endemic areas.

Methods

Serum samples were collected over a six-month period from twenty travellers having returned with falciparum malaria. Fourteen of these were malaria-naïve and six had a past history of one to two episodes of malaria. Antibodies to seven asexual stage P. falciparum antigens were measured by ELISA. Invasion inhibitory antibody responses to the 19kDa fragment of merozoite surface protein 1 (MSP119) were determined.

Results

Short-lived antibody responses were found in the majority of the subjects. While MSP119 antibodies were most common, MSP1 block 2 antibodies were significantly less frequent and recognized conserved domains. Antibodies to MSP2 cross-reacted to the dimorphic allelic families and anti-MSP2 isotypes were not IgG3 skewed as shown previously. MSP119 invasion inhibiting antibodies were present in 9/20 patients. A past history of malaria did not influence the frequency of these short-lived, functional antibodies (p = 0.2, 2-tailed Fisher's exact test).

Conclusion

Adults infected with P. falciparum for the first time, develop relatively short-lived immune responses that, in the case of MSP119, are functional. Antibodies to the polymorphic antigens studied were particularly directed to allelic family specific, non-repetitive and conserved determinants and were not IgG subclass skewed. These responses are substantially different to those found in malaria immune individuals.
Literature
1.
go back to reference Miller LH, Roberts T, Shahabuddin M, McCutchan TF: Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Mol Biochem Parasitol. 1993, 59: 1-14. 10.1016/0166-6851(93)90002-F.CrossRefPubMed Miller LH, Roberts T, Shahabuddin M, McCutchan TF: Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Mol Biochem Parasitol. 1993, 59: 1-14. 10.1016/0166-6851(93)90002-F.CrossRefPubMed
2.
go back to reference O'Donnell RA, de Koning-Ward TF, Burt RA, Bockarie M, Reeder JC, Cowman AF, Crabb BS: Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria. J Exp Med. 2001, 193: 1403-1412. 10.1084/jem.193.12.1403.PubMedCentralCrossRefPubMed O'Donnell RA, de Koning-Ward TF, Burt RA, Bockarie M, Reeder JC, Cowman AF, Crabb BS: Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria. J Exp Med. 2001, 193: 1403-1412. 10.1084/jem.193.12.1403.PubMedCentralCrossRefPubMed
3.
go back to reference Moore SA, Surgey EG, Cadwgan AM: Malaria vaccines: where are we and where are we going?. Lancet Infect Dis. 2002, 2: 737-743. 10.1016/S1473-3099(02)00451-6.CrossRefPubMed Moore SA, Surgey EG, Cadwgan AM: Malaria vaccines: where are we and where are we going?. Lancet Infect Dis. 2002, 2: 737-743. 10.1016/S1473-3099(02)00451-6.CrossRefPubMed
4.
go back to reference Conway DJ, Cavanagh DR, Tanabe K, Roper C, Mikes ZS, Sakihama N, Bojang KA, Oduola AM, Kremsner PG, Arnot DE, Greenwood BM, McBride JS: A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses. Nat Med. 2000, 6: 689-692. 10.1038/76272.CrossRefPubMed Conway DJ, Cavanagh DR, Tanabe K, Roper C, Mikes ZS, Sakihama N, Bojang KA, Oduola AM, Kremsner PG, Arnot DE, Greenwood BM, McBride JS: A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses. Nat Med. 2000, 6: 689-692. 10.1038/76272.CrossRefPubMed
5.
go back to reference Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, Rare L, Baisor M, Lorry K, Brown GV, Pye D, Irving DO, Smith TA, Beck HP, Alpers MP: A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis. 2002, 185: 820-827. 10.1086/339342.CrossRefPubMed Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, Rare L, Baisor M, Lorry K, Brown GV, Pye D, Irving DO, Smith TA, Beck HP, Alpers MP: A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis. 2002, 185: 820-827. 10.1086/339342.CrossRefPubMed
6.
go back to reference Wang L, Black CG, Marshall VM, Coppel RL: Structural and antigenic properties of merozoite surface protein 4 of Plasmodium falciparum. Infect Immun. 1999, 67: 2193-2200.PubMedCentralPubMed Wang L, Black CG, Marshall VM, Coppel RL: Structural and antigenic properties of merozoite surface protein 4 of Plasmodium falciparum. Infect Immun. 1999, 67: 2193-2200.PubMedCentralPubMed
7.
go back to reference Marshall VM, Tieqiao W, Coppel RL: Close linkage of three merozoite surface protein genes on chromosome 2 of Plasmodium falciparum. Mol Biochem Parasitol. 1998, 94: 13-25. 10.1016/S0166-6851(98)00045-0.CrossRefPubMed Marshall VM, Tieqiao W, Coppel RL: Close linkage of three merozoite surface protein genes on chromosome 2 of Plasmodium falciparum. Mol Biochem Parasitol. 1998, 94: 13-25. 10.1016/S0166-6851(98)00045-0.CrossRefPubMed
8.
go back to reference Goschnick MW, Black CG, Kedzierski L, Holder AA, Coppel RL: Merozoite surface protein 4/5 provides protection against lethal challenge with a heterologous malaria parasite strain. Infect Immun. 2004, 72: 5840-5849. 10.1128/IAI.72.10.5840-5849.2004.PubMedCentralCrossRefPubMed Goschnick MW, Black CG, Kedzierski L, Holder AA, Coppel RL: Merozoite surface protein 4/5 provides protection against lethal challenge with a heterologous malaria parasite strain. Infect Immun. 2004, 72: 5840-5849. 10.1128/IAI.72.10.5840-5849.2004.PubMedCentralCrossRefPubMed
9.
go back to reference Wang L, Crouch L, Richie TL, Nhan DH, Coppel RL: Naturally acquired antibody responses to the components of the Plasmodium falciparum merozoite surface protein 1 complex. Parasite Immunol. 2003, 25: 403-412. 10.1111/j.1365-3024.2003.00647.x.CrossRefPubMed Wang L, Crouch L, Richie TL, Nhan DH, Coppel RL: Naturally acquired antibody responses to the components of the Plasmodium falciparum merozoite surface protein 1 complex. Parasite Immunol. 2003, 25: 403-412. 10.1111/j.1365-3024.2003.00647.x.CrossRefPubMed
10.
go back to reference Topolska AE, Richie TL, Nhan DH, Coppel RL: Associations between responses to the rhoptry-associated membrane antigen of Plasmodium falciparum and immunity to malaria infection. Infect Immun. 2004, 72: 3325-3330. 10.1128/IAI.72.6.3325-3330.2004.PubMedCentralCrossRefPubMed Topolska AE, Richie TL, Nhan DH, Coppel RL: Associations between responses to the rhoptry-associated membrane antigen of Plasmodium falciparum and immunity to malaria infection. Infect Immun. 2004, 72: 3325-3330. 10.1128/IAI.72.6.3325-3330.2004.PubMedCentralCrossRefPubMed
11.
go back to reference Nixon CP, Friedman JF, Knopf PM, Duffy PE, Kurtis JD: Protective human immunity as a vaccine discovery tool for falciparum malaria. Transfusion. 2005, 45: 81S-87S. 10.1111/j.1537-2995.2005.00540.x.CrossRefPubMed Nixon CP, Friedman JF, Knopf PM, Duffy PE, Kurtis JD: Protective human immunity as a vaccine discovery tool for falciparum malaria. Transfusion. 2005, 45: 81S-87S. 10.1111/j.1537-2995.2005.00540.x.CrossRefPubMed
12.
go back to reference Eisen DP, Saul A, Fryauff DJ, Reeder JC, Coppel RL: Alterations in Plasmodium falciparum genotypes during sequential infections suggest the presence of strain specific immunity. Am J Trop Med Hyg. 2002, 67: 8-16.PubMed Eisen DP, Saul A, Fryauff DJ, Reeder JC, Coppel RL: Alterations in Plasmodium falciparum genotypes during sequential infections suggest the presence of strain specific immunity. Am J Trop Med Hyg. 2002, 67: 8-16.PubMed
13.
go back to reference Eisen D, Billman-Jacobe H, Marshall VF, Fryauff D, Coppel RL: Temporal variation of the merozoite surface protein-2 gene of Plasmodium falciparum. Infect Immun. 1998, 66: 239-246.PubMedCentralPubMed Eisen D, Billman-Jacobe H, Marshall VF, Fryauff D, Coppel RL: Temporal variation of the merozoite surface protein-2 gene of Plasmodium falciparum. Infect Immun. 1998, 66: 239-246.PubMedCentralPubMed
14.
go back to reference Burghaus PA, Holder AA: Expression of the 19-kilodalton carboxy-terminal fragment of the Plasmodium falciparum merozoite surface protein-1 in Escherichia coli as a correctly folded protein. Mol Biochem Parasitol. 1994, 64: 165-169. 10.1016/0166-6851(94)90144-9.CrossRefPubMed Burghaus PA, Holder AA: Expression of the 19-kilodalton carboxy-terminal fragment of the Plasmodium falciparum merozoite surface protein-1 in Escherichia coli as a correctly folded protein. Mol Biochem Parasitol. 1994, 64: 165-169. 10.1016/0166-6851(94)90144-9.CrossRefPubMed
15.
go back to reference Weisman S, Wang L, Billman-Jacobe H, Nhan DH, Richie TL, Coppel RL: Antibody responses to infections with strains of Plasmodium falciparum expressing diverse forms of merozoite surface protein 2. Infection and Immunity. 2001, 69: 959-967. 10.1128/IAI.69.2.959-967.2001.PubMedCentralCrossRefPubMed Weisman S, Wang L, Billman-Jacobe H, Nhan DH, Richie TL, Coppel RL: Antibody responses to infections with strains of Plasmodium falciparum expressing diverse forms of merozoite surface protein 2. Infection and Immunity. 2001, 69: 959-967. 10.1128/IAI.69.2.959-967.2001.PubMedCentralCrossRefPubMed
16.
go back to reference Egan AF, Chappel JA, Burghaus PA, Morris JS, McBride JS, Holder AA, Kaslow DC, Riley EM: Serum antibodies from malaria-exposed people recognize conserved epitopes formed by the two epidermal growth factor motifs of MSP1(19), the carboxy-terminal fragment of the major merozoite surface protein of Plasmodium falciparum. Infect Immun. 1995, 63: 456-466.PubMedCentralPubMed Egan AF, Chappel JA, Burghaus PA, Morris JS, McBride JS, Holder AA, Kaslow DC, Riley EM: Serum antibodies from malaria-exposed people recognize conserved epitopes formed by the two epidermal growth factor motifs of MSP1(19), the carboxy-terminal fragment of the major merozoite surface protein of Plasmodium falciparum. Infect Immun. 1995, 63: 456-466.PubMedCentralPubMed
17.
go back to reference Wang L, Richie TL, Stowers A, Nhan DH, Coppel RL: Naturally acquired antibody responses to Plasmodium falciparum merozoite surface protein 4 in a population living in an area of endemicity in Vietnam. Infect Immun. 2001, 69: 4390-4397. 10.1128/IAI.69.7.4390-4397.2001.PubMedCentralCrossRefPubMed Wang L, Richie TL, Stowers A, Nhan DH, Coppel RL: Naturally acquired antibody responses to Plasmodium falciparum merozoite surface protein 4 in a population living in an area of endemicity in Vietnam. Infect Immun. 2001, 69: 4390-4397. 10.1128/IAI.69.7.4390-4397.2001.PubMedCentralCrossRefPubMed
18.
go back to reference Jouin H, Rogier C, Trape JF, Mercereau-Puijalon O: Fixed, epitope-specific, cytophilic antibody response to the polymorphic block 2 domain of the Plasmodium falciparum merozoite surface antigen MSP-1 in humans living in a malaria-endemic area. Eur J Immunol. 2001, 31: 539-550. 10.1002/1521-4141(200102)31:2<539::AID-IMMU539>3.0.CO;2-1.CrossRefPubMed Jouin H, Rogier C, Trape JF, Mercereau-Puijalon O: Fixed, epitope-specific, cytophilic antibody response to the polymorphic block 2 domain of the Plasmodium falciparum merozoite surface antigen MSP-1 in humans living in a malaria-endemic area. Eur J Immunol. 2001, 31: 539-550. 10.1002/1521-4141(200102)31:2<539::AID-IMMU539>3.0.CO;2-1.CrossRefPubMed
19.
go back to reference Taylor RR, Smith DB, Robinson VJ, McBride JS, Riley EM: Human antibody response to Plasmodium falciparum merozoite surface protein 2 is serogroup specific and predominantly of the immunoglobulin G3 subclass. Infect Immun. 1995, 63: 4382-4388.PubMedCentralPubMed Taylor RR, Smith DB, Robinson VJ, McBride JS, Riley EM: Human antibody response to Plasmodium falciparum merozoite surface protein 2 is serogroup specific and predominantly of the immunoglobulin G3 subclass. Infect Immun. 1995, 63: 4382-4388.PubMedCentralPubMed
20.
go back to reference John CC, O'Donnell RA, Sumba PO, Moormann AM, de Koning-Ward TF, King CL, Kazura JW, Crabb BS: Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa. J Immunol. 2004, 173: 666-672.CrossRefPubMed John CC, O'Donnell RA, Sumba PO, Moormann AM, de Koning-Ward TF, King CL, Kazura JW, Crabb BS: Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa. J Immunol. 2004, 173: 666-672.CrossRefPubMed
21.
go back to reference Corran PH, O'Donnell RA, Todd J, Uthaipibull C, Holder AA, Crabb BS, Riley EM: The fine specificity, but not the invasion inhibitory activity, of 19-kilodalton merozoite surface protein 1-specific antibodies is associated with resistance to malarial parasitemia in a cross-sectional survey in The Gambia. Infect Immun. 2004, 72: 6185-6189. 10.1128/IAI.72.10.6185-6189.2004.PubMedCentralCrossRefPubMed Corran PH, O'Donnell RA, Todd J, Uthaipibull C, Holder AA, Crabb BS, Riley EM: The fine specificity, but not the invasion inhibitory activity, of 19-kilodalton merozoite surface protein 1-specific antibodies is associated with resistance to malarial parasitemia in a cross-sectional survey in The Gambia. Infect Immun. 2004, 72: 6185-6189. 10.1128/IAI.72.10.6185-6189.2004.PubMedCentralCrossRefPubMed
22.
go back to reference Perraut R, Marrama L, Diouf B, Sokhna C, Tall A, Nabeth P, Trape JF, Longacre S, Mercereau-Puijalon O: Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village. J Infect Dis. 2005, 191: 264-271. 10.1086/426398.CrossRefPubMed Perraut R, Marrama L, Diouf B, Sokhna C, Tall A, Nabeth P, Trape JF, Longacre S, Mercereau-Puijalon O: Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village. J Infect Dis. 2005, 191: 264-271. 10.1086/426398.CrossRefPubMed
23.
go back to reference Cavanagh DR, Dodoo D, Hviid L, Kurtzhals JA, Theander TG, Akanmori BD, Polley S, Conway DJ, Koram K, McBride JS: Antibodies to the N-terminal block 2 of Plasmodium falciparum merozoite surface protein 1 are associated with protection against clinical malaria. Infect Immun. 2004, 72: 6492-6502. 10.1128/IAI.72.11.6492-6502.2004.PubMedCentralCrossRefPubMed Cavanagh DR, Dodoo D, Hviid L, Kurtzhals JA, Theander TG, Akanmori BD, Polley S, Conway DJ, Koram K, McBride JS: Antibodies to the N-terminal block 2 of Plasmodium falciparum merozoite surface protein 1 are associated with protection against clinical malaria. Infect Immun. 2004, 72: 6492-6502. 10.1128/IAI.72.11.6492-6502.2004.PubMedCentralCrossRefPubMed
24.
go back to reference Cavanagh DR, Elhassan IM, Roper C, Robinson VJ, Giha H, Holder AA, Hviid L, Theander TG, Arnot DE, McBride JS: A longitudinal study of type-specific antibody responses to Plasmodium falciparum merozoite surface protein-1 in an area of unstable malaria in Sudan. J Immunol. 1998, 161: 347-359.PubMed Cavanagh DR, Elhassan IM, Roper C, Robinson VJ, Giha H, Holder AA, Hviid L, Theander TG, Arnot DE, McBride JS: A longitudinal study of type-specific antibody responses to Plasmodium falciparum merozoite surface protein-1 in an area of unstable malaria in Sudan. J Immunol. 1998, 161: 347-359.PubMed
25.
go back to reference Fluck C, Smith T, Beck HP, Irion A, Betuela I, Alpers MP, Anders R, Saul A, Genton B, Felger I: Strain-specific humoral response to a polymorphic malaria vaccine. Infect Immun. 2004, 72: 6300-6305. 10.1128/IAI.72.11.6300-6305.2004.PubMedCentralCrossRefPubMed Fluck C, Smith T, Beck HP, Irion A, Betuela I, Alpers MP, Anders R, Saul A, Genton B, Felger I: Strain-specific humoral response to a polymorphic malaria vaccine. Infect Immun. 2004, 72: 6300-6305. 10.1128/IAI.72.11.6300-6305.2004.PubMedCentralCrossRefPubMed
26.
go back to reference Felger I, Steiger S, Hatz C, Smith T, Beck HP: Antigenic cross-reactivity between different alleles of the Plasmodium falciparum merozoite surface protein 2. Parasite Immunol. 2003, 25: 531-543. 10.1111/j.0141-9838.2004.00664.x.CrossRefPubMed Felger I, Steiger S, Hatz C, Smith T, Beck HP: Antigenic cross-reactivity between different alleles of the Plasmodium falciparum merozoite surface protein 2. Parasite Immunol. 2003, 25: 531-543. 10.1111/j.0141-9838.2004.00664.x.CrossRefPubMed
27.
go back to reference Franks S, Baton L, Tetteh K, Tongren E, Dewin D, Akanmori BD, Koram KA, Ranford-Cartwright L, Riley EM: Genetic diversity and antigenic polymorphism in Plasmodium falciparum: extensive serological cross-reactivity between allelic variants of merozoite surface protein 2. Infect Immun. 2003, 71: 3485-3495. 10.1128/IAI.71.6.3485-3495.2003.PubMedCentralCrossRefPubMed Franks S, Baton L, Tetteh K, Tongren E, Dewin D, Akanmori BD, Koram KA, Ranford-Cartwright L, Riley EM: Genetic diversity and antigenic polymorphism in Plasmodium falciparum: extensive serological cross-reactivity between allelic variants of merozoite surface protein 2. Infect Immun. 2003, 71: 3485-3495. 10.1128/IAI.71.6.3485-3495.2003.PubMedCentralCrossRefPubMed
28.
go back to reference Metzger WG, Okenu DM, Cavanagh DR, Robinson JV, Bojang KA, Weiss HA, McBride JS, Greenwood BM, Conway DJ: Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria. Parasite Immunol. 2003, 25: 307-312. 10.1046/j.1365-3024.2003.00636.x.CrossRefPubMed Metzger WG, Okenu DM, Cavanagh DR, Robinson JV, Bojang KA, Weiss HA, McBride JS, Greenwood BM, Conway DJ: Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria. Parasite Immunol. 2003, 25: 307-312. 10.1046/j.1365-3024.2003.00636.x.CrossRefPubMed
29.
go back to reference Taylor RR, Allen SJ, Greenwood BM, Riley EM: IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. Am J Trop Med Hyg. 1998, 58: 406-413.PubMed Taylor RR, Allen SJ, Greenwood BM, Riley EM: IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. Am J Trop Med Hyg. 1998, 58: 406-413.PubMed
30.
go back to reference Staalsoe T, Megnekou R, Fievet N, Ricke CH, Zornig HD, Leke R, Taylor DW, Deloron P, Hviid L: Acquisition and decay of antibodies to pregnancy-associated variant antigens on the surface of Plasmodium falciparum-infected erythrocytes that protect against placental parasitemia. J Infect Dis. 2001, 184: 618-626. 10.1086/322809.CrossRefPubMed Staalsoe T, Megnekou R, Fievet N, Ricke CH, Zornig HD, Leke R, Taylor DW, Deloron P, Hviid L: Acquisition and decay of antibodies to pregnancy-associated variant antigens on the surface of Plasmodium falciparum-infected erythrocytes that protect against placental parasitemia. J Infect Dis. 2001, 184: 618-626. 10.1086/322809.CrossRefPubMed
Metadata
Title
Antibodies elicited in adults by a primary Plasmodium falciparum blood-stage infection recognize different epitopes compared with immune individuals
Authors
Damon P Eisen
Lina Wang
Helene Jouin
E Elsa H Murhandarwati
Casilda G Black
Odile Mercereau-Puijalon
Ross L Coppel
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2007
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/1475-2875-6-86

Other articles of this Issue 1/2007

Malaria Journal 1/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.